Shares of Natus Medical Incorporated (NASDAQ:NTUS) have earned a consensus broker rating score of 3.00 (Hold) from the one analysts that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation.
Zacks has also assigned Natus Medical an industry rank of 63 out of 255 based on the ratings given to related companies.
A number of equities analysts have recently weighed in on the company. ValuEngine upgraded Natus Medical from a “sell” rating to a “hold” rating in a research note on Friday, February 21st. Zacks Investment Research downgraded Natus Medical from a “hold” rating to a “sell” rating in a research note on Wednesday, February 12th.
NTUS stock traded down $0.58 during midday trading on Friday, reaching $28.20. 113,300 shares of the company were exchanged, compared to its average volume of 137,808. Natus Medical has a one year low of $22.25 and a one year high of $34.89. The firm has a market capitalization of $1.01 billion, a price-to-earnings ratio of -104.44 and a beta of 0.74. The business has a 50-day moving average price of $32.12 and a two-hundred day moving average price of $31.60. The company has a debt-to-equity ratio of 0.08, a current ratio of 1.89 and a quick ratio of 1.39.
Natus Medical (NASDAQ:NTUS) last issued its quarterly earnings data on Thursday, February 6th. The company reported $0.46 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.47 by ($0.01). Natus Medical had a negative net margin of 1.79% and a positive return on equity of 10.54%. The company had revenue of $131.76 million during the quarter, compared to the consensus estimate of $130.00 million. During the same period in the previous year, the company earned $0.43 earnings per share. Natus Medical’s revenue for the quarter was down 6.5% compared to the same quarter last year. As a group, analysts anticipate that Natus Medical will post 1.5 earnings per share for the current fiscal year.
In other news, CEO Jonathan Kennedy sold 6,684 shares of the business’s stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $31.54, for a total value of $210,813.36. Following the completion of the sale, the chief executive officer now owns 148,441 shares of the company’s stock, valued at $4,681,829.14. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 1.65% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in NTUS. Janus Henderson Group PLC acquired a new stake in shares of Natus Medical in the fourth quarter valued at approximately $58,950,000. Cramer Rosenthal Mcglynn LLC acquired a new stake in Natus Medical during the fourth quarter worth approximately $45,658,000. State Street Corp acquired a new stake in Natus Medical during the fourth quarter worth approximately $39,079,000. Victory Capital Management Inc. bought a new position in Natus Medical during the 4th quarter worth $33,687,000. Finally, Bank of New York Mellon Corp bought a new position in Natus Medical during the 4th quarter worth $22,851,000. 90.92% of the stock is currently owned by institutional investors.
About Natus Medical
Natus Medical Incorporated provides neurology, newborn care, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction and neurosurgical treatments, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.
Recommended Story: What member countries make up the G-20?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.